Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.54 |
| ▸ | JAK2 | O60674 | 4/20 | 0.54 |
| ▸ | GSK3B | P49841 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515585 | 0.90 | ROCK2 (0.51) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL3190345 | 0.88 | MAPT (0.49) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL15514928 | 0.81 | CYP3A4 (0.46) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL24172739 | 0.80 | CYP3A4 (0.58) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL15515501 | 0.80 | CYP3A4 (0.58) | ROCK2JAK2GSK3BCYP3A4NOS1 | |
| SCHEMBL5823182 | 0.77 | CYP3A4 (0.55) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL4590575 | 0.74 | ROCK2 (0.52) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL2798618 | 0.74 | CDC7 (0.59) | ROCK2CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31542339 | 0.73 | CYP3A4 (0.52) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL2257000 | 0.73 | CYP2D6 (0.68) | ROCK2JAK2GSK3BCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ROCK2 4658/4885JAK2 2800/4885GSK3B 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.